Overall SDG Alignment Evaluation:
The Master of Science Program in Pharmacology (International Program) is intrinsically aligned with the Sustainable Development Goals, focusing on the discovery, development, and safe use of medicines to improve human health. The curriculum is designed to produce researchers and experts who can innovate and lead in addressing critical health challenges on a global scale. The program makes a foundational contribution to SDG 3 (Good Health and Well-being) by advancing knowledge in drug action, pharmacogenomics, and the treatment of major diseases like cancer and cardiovascular disorders. It is a strong driver for SDG 9 (Industry, Innovation and Infrastructure) through its focus on drug discovery, medical biotechnology, and advanced research methodologies, which enhance scientific research and upgrade the technological capabilities of the pharmaceutical and healthcare industries. As an advanced research-based international degree, the program is a pillar of SDG 4 (Quality Education), fostering a new generation of pharmacologists prepared for global collaboration. Furthermore, its emphasis on research collaboration and the dissemination of new knowledge embodies the cooperative spirit of SDG 17 (Partnerships for the Goals).
SDG 3: Good Health and Well-beingAlignment Summary: This program is central to promoting good health by advancing the science of pharmacology, which is the foundation of modern medicine. The curriculum equips graduates with the knowledge to research and develop new drugs, understand their mechanisms of action, and promote their safe and effective use, directly contributing to the fight against both communicable and non-communicable diseases on a global scale.
| Course Code | Course Title | Alignment Rationale |
|---|---|---|
| MD667 713 | Clinical Pharmacology | Supports universal health coverage (Target 3.8) by focusing on the principles of safe and effective drug use in humans, including clinical trials and post-marketing surveillance. |
| MD667 722 | Advanced Pharmacology | Directly supports the management of non-communicable diseases by providing in-depth knowledge on the treatment of conditions like cancer and cardiovascular disease (Target 3.4). |
| MD667 724 | Pharmacogenomics and Precision Medicine | Contributes to health and well-being by advancing personalized medicine, which can improve treatment efficacy and reduce adverse drug reactions (Target 3.8). |
| MD667 725 | Cardiovascular Pharmacology | Aligns with good health by providing specialized knowledge in managing cardiovascular diseases, a leading cause of premature mortality (Target 3.4). |
| MD637 716 | Medical Biotechnology | Supports Target 3.b by focusing on the research and development of vaccines, medicines, and other medical biotechnologies. |
SDG 4: Quality EducationAlignment Summary: As an international Master of Science program, this curriculum provides high-quality, specialized education in pharmacology. It is designed to equip students from diverse backgrounds with the research, technical, and analytical skills necessary for high-level employment in academia and the pharmaceutical industry, fostering a culture of lifelong learning and scientific advancement.
| Course Code | Course Title | Alignment Rationale |
|---|---|---|
| MD567 714 | Medical Science Research Methodology | Directly supports Target 4.4 by providing students with the advanced technical and research skills required for relevant, high-level employment and entrepreneurship in the field of pharmacology. |
| MD667 891 / 892 | Seminar in Pharmacology I / II | Enhances lifelong learning opportunities (Target 4.3) by training students in critical analysis, scientific discourse, and the communication of complex research findings. |
| MD667 898 / 899 | Thesis | Represents a capstone lifelong learning opportunity where students conduct original research, thereby acquiring superior technical skills for employment and contributing new knowledge to the field (Target 4.4). |
SDG 9: Industry, Innovation and InfrastructureAlignment Summary: This program is a catalyst for innovation in the pharmaceutical and biotechnology industries. It focuses on the entire drug development pipeline, from molecular mechanisms to clinical application, enhancing scientific research and upgrading the technological capabilities of the sector to foster a more resilient and innovative industry.
| Course Code | Course Title | Alignment Rationale |
|---|---|---|
| MD667 728 | Molecular Pharmacology | Supports Target 9.5 by enhancing scientific research and upgrading technological capabilities through the study of drug action at the molecular level, which is fundamental to modern drug discovery. |
| MD637 716 | Medical Biotechnology | Promotes innovation and sustainable industrialization (Target 9.4) by focusing on the development and application of advanced biotechnologies in medicine. |
| MD627 732 | Bioinformatics | Contributes to upgrading the technological capabilities of the research sector (Target 9.5) by providing skills in computational analysis of biological data, which is essential for modern drug development. |
SDG 17: Partnerships for the GoalsAlignment Summary: The international and research-intensive nature of this program inherently fosters partnerships for sustainable development. Through seminar and thesis work, students engage with the global scientific and medical communities, promoting the knowledge-sharing and multi-stakeholder collaborations vital for addressing the complex, interconnected challenges of global health and pharmacology.
| Course Code | Course Title | Alignment Rationale |
|---|---|---|
| MD667 891 / 892 | Seminar in Pharmacology I / II | Enhances the global partnership for sustainable development by having students from various countries present and discuss cutting-edge research, contributing to the international body of scientific knowledge (Target 17.6). |
| MD667 898 / 899 | Thesis | Represents a significant contribution to global partnerships (Target 17.17) by creating new, publishable knowledge that is shared internationally to help solve critical health challenges through pharmacological research. |